Indoleamine 2,3-dioxygenase expression and activity in patients with hepatitis C virus-induced liver cirrhosis

Asghar,Kashif; Ashiq,M.   Taimour; Zulfiqar,Bilal; Mahroo,Amnah; Nasir,Kaenat; Murad,Sheeba

doi:10.3892/etm.2014.2146

Indoleamine 2,3-dioxygenase expression and activity in patients with hepatitis C virus-induced liver cirrhosis

Authors:
- Kashif Asghar
- M. Taimour Ashiq
- Bilal Zulfiqar
- Amnah Mahroo
- Kaenat Nasir
- Sheeba Murad
View Affiliations

Affiliations: Molecular immunology Research Group, Atta-ur-Rahman School of Applied Biosciences (ASAB), National University of Sciences & Technology (NUST), Islamabad 44000, Pakistan
Published online on: December 18, 2014 https://doi.org/10.3892/etm.2014.2146
Pages: 901-904

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Indoleamine 2,3‑dioxygenase (IDO) is an immunoregulatory enzyme. It plays a key role in various malignancies, infection and autoimmune diseases. IDO induces immunosuppression through the depletion of tryptophan and its downstream metabolites. Hepatitis C virus (HCV) has infected more than 12 million individuals in Pakistan. The aim of the present study was to assess the expression and activity of IDO in HCV‑infected patients. The functional enzymatic activity of IDO was measured by colorimetric assay. Serum samples from 100 HCV‑infected patients were taken to examine IDO activity and samples from 100 healthy volunteers were used as controls. Liver sections from patients with HCV (n=35) and healthy controls (n=5) were used for immunohistochemical studies. Immunohistochemical analysis revealed that IDO was overexpressed in 28 of 35 (80%) cirrhotic liver samples, whereas 5 of 35 (14.2%) cases presented moderate and 2 of 35 (5.7%) cases presented mild expression of IDO. The enzymatic activity of IDO was significantly higher in the serum samples of HCV‑infected patients as compared with those in the control. These data indicate that the expression of IDO correlated with the pathogenesis of disease. In summary, it is suggested that the high expression of IDO in the progressively cirrhotic livers of HCV‑infected patients might contribute to the development of hepatocellular carcinoma. IDO may characterize a novel therapeutic target against HCV.

View Figures

View References

1	Tan SL, Pause A, Shi Y and Sonenberg N: Hepatitis C therapeutics: current status and emerging strategies. Nat Rev Drug Discov. 1:867–881. 2002. View Article : Google Scholar : PubMed/NCBI
2	Alter HJ and Seef LB: Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis. 20:17–35. 2000. View Article : Google Scholar : PubMed/NCBI
3	Lauer GM and Walker BD: Hepatitis C virus infection. N Engl J Med. 345:41–52. 2001. View Article : Google Scholar : PubMed/NCBI
4	El-Serag HB: Hepatocellular carcinoma and hepatitis C in the United States. Hepatology. 36(5 Suppl 1): S74–S83. 2002. View Article : Google Scholar : PubMed/NCBI
5	Bowen DG and Walker CM: Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature. 436:946–952. 2005. View Article : Google Scholar : PubMed/NCBI
6	Stone TW and Darlington LG: Endogenous kynurenines as targets for drug discovery and development. Nat Rev Drug Discov. 1:609–620. 2002. View Article : Google Scholar : PubMed/NCBI
7	Robinson CM, Shirey KA and Carlin JM: Synergistic transcriptional activation of indoleamine dioxygenase by IFG-gamma and tumor necrosis factor-alpha. J Interferon Cytokine Res. 23:413–421. 2003. View Article : Google Scholar : PubMed/NCBI
8	Abbate I, Romano M, Longo R, et al: Endogenous levels of mRNA for IFNs and IFN-related genes in hepatic biopsies of chronic HCV-infected and non-alcoholic steatohepatitis patients. J Med Virol. 70:581–587. 2003. View Article : Google Scholar : PubMed/NCBI
9	Grohmann U, Fallarino F and Puccetti P: Tolerance, DCs and tryptophan: much ado about IDO. Trends Immunol. 24:242–248. 2003. View Article : Google Scholar : PubMed/NCBI
10	Munn DH, Sharma MD and Mellor AL: Ligation of B7-1/B7-2 by human CD4⁺ T cells trigger indoleamine 2,3-dioxgenase activity in dendritic cells. J Immunol. 172:4100–4110. 2004. View Article : Google Scholar : PubMed/NCBI
11	Mellor AL and Munn DH: IDO expression by DCs: tolerance and tryptophan catabolism. Nat Rev Immunol. 4:762–774. 2004. View Article : Google Scholar : PubMed/NCBI
12	Uyttenhove C, Pilotte L, Théate I, et al: Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxgenase. Nat Med. 9:1269–1274. 2003. View Article : Google Scholar : PubMed/NCBI
13	Larrea E, Riezu-Boj JI, Gil-Guerrero L, et al: Upregulation of indoleamine 2,3-dioxgenase in hepatitis C virus infection. J Virol. 81:3662–3666. 2007. View Article : Google Scholar : PubMed/NCBI
14	Sugimoto K, Ikeda F, Stadanlick J, et al: Suppression of HCV-specific T-cells without differential hierarchy demonstrated ex vivo in persistent HCV infection. Hepatology. 38:1437–1448. 2003.PubMed/NCBI
15	Perrella A, Vitiello L, Atripaldi L, et al: Elevated CD4⁺/CD25⁺ T cell frequency and function during acute hepatitis C presage chronic evolution. Gut. 55:1370–1371. 2006. View Article : Google Scholar : PubMed/NCBI
16	Ulsenheimer A, Gerlach JT, Gruener NH, et al: Detection of functionally altered hepatitis C virus-specific CD4 T cells in acute and chronic hepatitis C. Hepatology. 37:1189–1198. 2003. View Article : Google Scholar : PubMed/NCBI
17	Cabrera R, Tu Z, Xu Y, et al: An immunomodulatory role for CD4⁺, CD25⁺, regulatory T lymphocytes in hepatitis C virus infection. Hepatology. 40:1062–1071. 2004. View Article : Google Scholar : PubMed/NCBI
18	Boettler T, Spangenberg HC, Neumann-Haefelin C, et al: T cells with a CD4⁺CD25⁺ regulatory phenotype suppress in vitro proliferation of virus-specific CD⁺ T cells during chronic hepatitis C virus infection. J Virol. 79:7860–7867. 2005. View Article : Google Scholar : PubMed/NCBI
19	Bolacchi F, Sinistro A, Ciaprini C, et al: Increased hepatitis C virus (HCV)-specific CD4⁺ CD25⁺ regulatory T lymphocytes and reduced HCV-specific CD4⁺ T cell response in HCV-infected patients with normal versus abnormal alanine aminotransferase levels. Clin Exp Immunol. 144:188–196. 2006. View Article : Google Scholar : PubMed/NCBI
20	Ebinuma H, Nakamoto N, Li Y, et al: Identification and in vitro expansion of functional antigen-specific CD25⁺ FoxP3⁺ regulatory T-cells in hepatitis C virus infection. J Virol. 82:5043–5053. 2008. View Article : Google Scholar : PubMed/NCBI
21	Fallarino F, Grohmann U, You S, et al: The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T-cell receptor zeta-chain and induce a regulatory phenotype in naïve T cells. J Immunol. 176:6752–6761. 2006. View Article : Google Scholar : PubMed/NCBI
22	Hill M, Tanguy-Royer S, Royer P, et al: IDO expands human CD4⁺CD25 high regulatory T cells by promoting maturation of LPS-treated dendritic cells. Eur J Immunol. 37:3054–3062. 2007. View Article : Google Scholar : PubMed/NCBI
23	Sharma MD, Baban B, Chandler P, et al: Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxgenase. J Clin Invest. 117:2570–2582. 2007. View Article : Google Scholar : PubMed/NCBI
24	Terness P, Bauer TM, Röse L, et al: Inhibition of allogenic T cell proliferation by indoleamine 2,3-dioxgenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites. J Exp Med. 447–457. 2002. View Article : Google Scholar
25	Munn DH and Mellor AL: IDO and tolerance to tumors. Trends Mol Med. 10:15–18. 2004. View Article : Google Scholar : PubMed/NCBI
26	Takikawa O, Kuroiwa T, Yamazaki F and Kido R: Mechanism of interferon-gamma action. characterization of indoleamine 2,3-dioxygenase in cultured human cells induced by interferon-gamma and evaluation of the enzyme-mediated tryptophan degradation in its anticellular activity. J Biol Chem. 263:2041–2048. 1988.PubMed/NCBI
27	Grant RS, Naif H, Thuruthyil SJ, et al: Induction of indolamine 2,3-dioxygenase in primary human macrophages by human immunodeficiency virus type 1 is strain dependent. J Virol. 74:4110–4115. 2000. View Article : Google Scholar
28	Fallarino F, Vacca C, Orabona C, et al: Functional expression of indoleamine 2,3-dioxygenase by murine CD8 alpha⁺ dendritic cells. Int Immunol. 14:65–68. 2002. View Article : Google Scholar
29	Grohmann U, Bianchi R, Orabona C, et al: Functional plasticity of dendritic cell subsets as mediated by CD40 versus B7 activation. J Immunol. 171:2581–2587. 2003. View Article : Google Scholar : PubMed/NCBI
30	Pan K, Wang H, Chen MS, et al: Expression and prognosis role of indoleamine 2,3-dioxygenase in hepatocellular carcinoma. J Cancer Res Clin. 134:1247–1253. 2008. View Article : Google Scholar
31	Day CL, Lauer GM, Robbins GK, et al: Broad specificity of virus-specific CD4+ T-helper-cell responses in resolved hepatitis C virus infection. J Virol. 76:12584–12595. 2002. View Article : Google Scholar : PubMed/NCBI
32	Semmo N and Klenerman P: CD4+ T cell responses in hepatitis C virus infection. World J Gastroenterol. 13:4831–4838. 2007.PubMed/NCBI
33	Chang KM, Thimme R, Melpolder JJ, Oldach D, et al: Differential CD4 (+) and CD8(+) T-cell responsiveness in hepatitis C virus infection. Hepatology. 33:267–276. 2001. View Article : Google Scholar
34	Perrella A, Vitiello L, Atripaldi L, et al: Elevated CD4⁺/CD25⁺ T cell frequency and function during acute hepatitis C presage chronic evolution. Gut. 55:1370–1371. 2006. View Article : Google Scholar : PubMed/NCBI
35	Ino K, Yoshida N, Kajiyama H, et al: Indoleamine 2,3-dioxygenase is a novel prognostic indicator for dendometrial cancer. Br J Cancer. 95:1555–1561. 2006. View Article : Google Scholar : PubMed/NCBI
36	Brandacher G, Perathoner A, Ladurner R, et al: Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Clin Cancer Res. 12:1144–1151. 2006. View Article : Google Scholar : PubMed/NCBI
37	Ishio T, Goto S, Tahara K, et al: Immunoactivative role of indoleamine 2,3-dioxygenase in human hepatocellular carcinoma. J Gastroenterol Hepatol. 19:319–326. 2004. View Article : Google Scholar : PubMed/NCBI